CLINICAL TRIALS PROFILE FOR ACTHAR GEL
✉ Email this page to a colleague
All Clinical Trials for acthar gel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00805753 ↗ | Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy | Completed | Mallinckrodt | Phase 1 | 2009-01-01 | This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN. ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland (a gland at the base of your brain) that is involved in stimulating your adrenal glands to secrete a number of steroid products (e.g. cortisol, aldosterone, corticosterone, and others) that are important in keeping you alive. The drug used in this study has been approved by the Food and Drug Administration (FDA) for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN. However, the most adequate dose to use has not been adequately assessed. This is the reason for conducting this research study. |
| NCT00805753 ↗ | Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy | Completed | Mayo Clinic | Phase 1 | 2009-01-01 | This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN. ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland (a gland at the base of your brain) that is involved in stimulating your adrenal glands to secrete a number of steroid products (e.g. cortisol, aldosterone, corticosterone, and others) that are important in keeping you alive. The drug used in this study has been approved by the Food and Drug Administration (FDA) for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN. However, the most adequate dose to use has not been adequately assessed. This is the reason for conducting this research study. |
| NCT00854750 ↗ | Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis | Terminated | Mallinckrodt | Phase 4 | 2009-05-01 | The investigators principal hypothesis is that INO and optic neuritis are objective, quantitative, and reproducible models for corroborating the hypothesis that changes in core body temperature are associated with the reversible and stereotypic decay in axonal conduction and that ACTHAR can serve to prevent such changes. The application of ocular motor and optic nerve measures appears to constitute a useful paradigm to detect and monitor responses to therapeutic strategies that stabilize nerve cell membranes in response to temperature induced decay in axonal conduction mechanisms, with implications on activities of daily life that are dependent upon vision (reading, driving, walking, work performance). |
| NCT00854750 ↗ | Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis | Terminated | Elliot Frohman | Phase 4 | 2009-05-01 | The investigators principal hypothesis is that INO and optic neuritis are objective, quantitative, and reproducible models for corroborating the hypothesis that changes in core body temperature are associated with the reversible and stereotypic decay in axonal conduction and that ACTHAR can serve to prevent such changes. The application of ocular motor and optic nerve measures appears to constitute a useful paradigm to detect and monitor responses to therapeutic strategies that stabilize nerve cell membranes in response to temperature induced decay in axonal conduction mechanisms, with implications on activities of daily life that are dependent upon vision (reading, driving, walking, work performance). |
| NCT01021540 ↗ | Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes | Completed | Arizona Kidney Disease and Hypertension Center | Phase 4 | 2009-12-01 | To determine if H.P. Acthar Gel (repository corticotrophin) has the same anti-proteinuric effects seen with the synthetic ACTH analogue in Europe. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for acthar gel
Condition Name
Clinical Trial Locations for acthar gel
Trials by Country
Clinical Trial Progress for acthar gel
Clinical Trial Phase
Clinical Trial Sponsors for acthar gel
Sponsor Name
